U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. The Wellness Center Pharmacy, Inc., dba Designer Drugs - 496523 - 02/06/2019
  1. Warning Letters

CLOSEOUT LETTER

The Wellness Center Pharmacy, Inc., dba Designer Drugs MARCS-CMS 496523 —

Product:
Drugs
Recipient:
Recipient Name
Randal J. Davis
Recipient Title
President
The Wellness Center Pharmacy, Inc., dba Designer Drugs

7304 Jarnigan Road
Chattanooga, TN 37421
United States

Issuing Office:
Center for Drug Evaluation and Research

United States

Dear Mr. Davis:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter #2016-NOL-11 dated August 5, 2016. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Jose R. Lopez
Acting Director, Compliance Branch
Office of Pharmaceutical Quality Operations
Division II

Back to Top